Vol. 6, Issue 1, Part A (2023)
The potential role of villin 1 and estrogen receptor (ER) in differentiation between endocervical adenocarcinoma and endometrial adenocarcinoma
Author(s):
Mai Elshenawy Elsemelawy, Aymen Mohamed El-Saka, Ahmed Abdel Azeim Menaisy and Asmaa Mustafa Eid
Abstract:
Background: Endocervical adenocarcinoma (ECAC) is the 4th most common cancer in females globally. It has been ranked the 14th most common cancer in Egyptian females. The aim of this work was to study immunohistochemical expression of villin1 in endocervical and endometrial adenocarcinoma, immunohistochemical expression of ER in endocervical and endometrial adenocarcinoma and evaluate the potential role of villin 1 and ER expression in differentiation between endocervical & endometrial adenocarcinoma.
Methods: This retrospective study was carried out on 60 cases of endocervical & endometrial endometroid adenocarcinoma. Patients were classified into two equal groups: Group I: Cases of endocervical adenocarcinomas and Group II: Cases of endometrial endometroid adenocarcinomas.
Results: The positive predictive value of ER as a correlation between ER expression and clinicopathological characteristics has been addressed in our study was 100%. The negative predictive value was 73.1%. The positive predictive value of using panel of villin and ER expression and clinicopathological characteristics has been addressed in our study was 88.8%, the negative predictive value was 66.6%.
Conclusions: Villin1 is good diagnostic tool had high specificity in differentiating endocervical and endometroid adenocarcinoma and has a predictive value in ECAC. ER is good diagnostic tool in differentiating between endocervical and endometroid adenocarcinomas and has predictive value in endometroid adenocarcinoma.
Pages: 20-26 | 633 Views 238 Downloads
How to cite this article:
Mai Elshenawy Elsemelawy, Aymen Mohamed El-Saka, Ahmed Abdel Azeim Menaisy and Asmaa Mustafa Eid. The potential role of villin 1 and estrogen receptor (ER) in differentiation between endocervical adenocarcinoma and endometrial adenocarcinoma. Int. J. Clin. Diagn. Pathol. 2023;6(1):20-26. DOI: 10.33545/pathol.2023.v6.i1a.506